Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health
A Single-Arm Clinical Trial Investigating the Feasibility of a Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health
A Single-Arm Clinical Trial Investigating the Feasibility of a Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Hybrid PET/MR in the Therapy of Cervical Cancer
Hybrid PET/MR in the Therapy of Cervical Cancer: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Hybrid PET/MR in the Therapy of Cervical Cancer
Hybrid PET/MR in the Therapy of Cervical Cancer: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer
Psychosexual Intervention for Gynecologic and Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer
Psychosexual Intervention for Gynecologic and Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Methotrexate and Mycophenolate Mofetil for UVEITIS
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Methotrexate and Mycophenolate Mofetil for UVEITIS
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Methotrexate and Mycophenolate Mofetil for UVEITIS
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
Status: Enrolling
Updated:  12/31/1969
Oregon Health & Science University, Casey Eye Institute
mi
from
Portland, OR
Methotrexate and Mycophenolate Mofetil for UVEITIS
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
Status: Enrolling
Updated: 12/31/1969
Oregon Health & Science University, Casey Eye Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Methotrexate and Mycophenolate Mofetil for UVEITIS
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
Status: Enrolling
Updated:  12/31/1969
Royal Victorian Eye and Ear Hospital
mi
from
Melbourne,
Methotrexate and Mycophenolate Mofetil for UVEITIS
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
Status: Enrolling
Updated: 12/31/1969
Royal Victorian Eye and Ear Hospital
mi
from
Melbourne,
Click here to add this to my saved trials
Methotrexate and Mycophenolate Mofetil for UVEITIS
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
Status: Enrolling
Updated:  12/31/1969
Francis I. Proctor Foundation
mi
from
San Francisco, CA
Methotrexate and Mycophenolate Mofetil for UVEITIS
First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
Status: Enrolling
Updated: 12/31/1969
Francis I. Proctor Foundation
mi
from
San Francisco, CA
Click here to add this to my saved trials
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
University of California Davis
mi
from
Davis, CA
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
University of California Davis
mi
from
Davis, CA
Click here to add this to my saved trials
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
University of California, Irivine
mi
from
Irvine, CA
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
University of California, Irivine
mi
from
Irvine, CA
Click here to add this to my saved trials
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Uterine Leiomyoma Treatment With Radiofrequency Ablation
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
A Randomized Trial of a Family Caregiver Palliative Care Intervention
Status: Enrolling
Updated:  12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
A Randomized Trial of a Family Caregiver Palliative Care Intervention
Status: Enrolling
Updated: 12/31/1969
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
USC Norris Hospital and LAC+USC Medical Center
mi
from
Los Angeles, CA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
USC Norris Hospital and LAC+USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of California, Irvine Medical Center
mi
from
Orange, CA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Women's Cancer Center
mi
from
Covington, LA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Women's Cancer Center
mi
from
Covington, LA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Institute
mi
from
New York, NY
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Hope Women's Cancer Centers / Mission Hospital, Inc.
mi
from
Asheville, NC
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Hope Women's Cancer Centers / Mission Hospital, Inc.
mi
from
Asheville, NC
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Levine Cancer Institute
mi
from
Charlotte, NC
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Peggy and Charles Oklahoma Cancer Center
mi
from
Oklahoma City, OK
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Peggy and Charles Oklahoma Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Hollings Cancer Center, MUSC
mi
from
Charleston, SC
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Hollings Cancer Center, MUSC
mi
from
Charleston, SC
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Sanford Research/USD
mi
from
Sioux Falls, SD
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Sanford Research/USD
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Inova Fairfax Hospitals
mi
from
Falls Church, VA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Inova Fairfax Hospitals
mi
from
Falls Church, VA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Henrico Doctor's Hospital
mi
from
Richmond, VA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Henrico Doctor's Hospital
mi
from
Richmond, VA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Aurora, CO
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Medizinische Universität Innsbruck
mi
from
Innsbruck,
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Medizinische Universität Innsbruck
mi
from
Innsbruck,
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Washington University School of medecine
mi
from
Saint Louis, MO
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Washington University School of medecine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Scottsdale, AZ
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sedona, AZ
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sedona, AZ
Click here to add this to my saved trials
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hot Springs, AR
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hot Springs, AR
Click here to add this to my saved trials
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greenbrae, CA
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greenbrae, CA
Click here to add this to my saved trials